Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 603 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Extension of Indications for Durvalumab in the Management of... October 25, 2023 FDA Approves Nivolumab in Combination with Chemotherapy and Nivolumab in Combination... June 8, 2022 Accepting Help During Cancer Is Hard, But It Can Benefit You... January 19, 2023 Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients... February 17, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Selpercatinib Preliminary Evidence of Efficacy of an Upfront ICI-based Therapeutic Strategy in... T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... Artificial Intelligence Expedites Brain Tumor Diagnosis during Surgery
